8-K ·Filed Aug 10, 2026

NUS

NU SKIN ENTERPRISES, INC.
BEARISH
Impact 7/10
Horizonweeks Processed1mo ago SEC0001140361-26-032025
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The accelerating revenue decline (12% in Q1 → 17% in Q2), combined with a massive goodwill impairment and a slashed full-year guidance, signals a structurally deteriorating business with no near-term catalyst. Traders should expect continued selling pressure as the market prices in further downside. The $137.3M buyback authorization is unlikely to provide support given the company's cash burn and declining fundamentals. Monitor Q3 results for any stabilization in customer/affiliate metrics or progress on the Prysm iO and India launch initiatives.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
NUS ▼ -0.41% at T+20d
SHORT call ✓ call won +0.41% · α vs SPY -0.65% · entry $4.87 → $4.85
Next anchor: T+60d in 4w
Latest observation: T+34 -11.42% FF3 residual α
Entry anchored
Aug 10, 04:15 PM ET
via 1-min bar
T+1d
-0.41%
call +0.41% · α +0.66%
$4.85
settled 8w ago
T+5d
-3.49%
call +3.49% · α +3.09%
$4.70
settled 7w ago
T+20d
-0.41%
call +0.41% · α -0.65%
$4.85
settled 25d ago
T+60d
—
call — · α —
—
in 4w

Price Chart

Loading chart...

Executive Summary

Nu Skin Enterprises reported Q2 2026 adjusted EPS of $0.20, a 37.5% miss vs the $0.32 consensus, on revenue of $320.1M, a 17.1% YoY decline and well below the $375.5M estimate. The company also recorded a massive GAAP net loss of -$249.8M driven by a $78.9M impairment and a $167.5M valuation allowance on deferred tax assets, and slashed its full-year 2026 revenue guidance to $1.28-$1.35B (from $1.35-$1.50B) and adjusted EPS to $0.70-$0.90 (from $0.80-$1.20). The business continues to deteriorate across all segments with customers, paid affiliates, and sales leaders all declining double-digits year-over-year, making this a clear bearish signal for the stock.

Key Financial Metrics

EPS
$0.20
est $0.32 · -37.5%
Revenue
$320.1M
est $375.5M · -14.8% · -17.1% YoY
Rating
miss
Guidance
$1.28B to $1.35B
lowered
Gross Margin
68.2%

Key Facts

  • Q2 2026 revenue of $320.1M declined 17.1% YoY from $386.1M, missing the $375.5M consensus.
  • Adjusted EPS (excluding impairment and tax charges) was $0.20, missing the $0.32 consensus estimate by 37.5%.
  • GAAP net loss was -$249.8M, or -$5.14 per share, driven by a $78.9M impairment charge and a $167.5M valuation allowance on deferred tax assets.
  • Full-year 2026 revenue guidance was lowered to $1.28-$1.35B (from $1.35-$1.50B), and adjusted EPS guidance was cut to $0.70-$0.90 (from $0.80-$1.20).
  • Total customers fell 14% YoY to 660,037; paid affiliates declined 8% to 120,291; sales leaders dropped 9% to 26,998.
  • All geographic segments reported revenue declines, with South Korea (-24.8%), Rhyz Manufacturing (-23.2%), and Americas (-18.1%) leading the drop.
  • Goodwill was slashed from $83.6M to $4.8M, reflecting a massive impairment.
  • No stock repurchases were made in Q2 2026, with $137.3M remaining in authorization.
  • The prior quarter (Q1 2026) already showed a 12% revenue decline and EPS of just $0.04 GAAP / $0.14 adjusted, confirming the accelerating downtrend.

Financial Impact

Q2 revenue miss of ~$55M vs consensus; full-year guidance cut by ~$160M at midpoint; GAAP net loss of -$249.8M driven by $78.9M impairment and $167.5M tax valuation allowance

revenueepsguidancegoodwillcustomerspaid affiliatessales leaders

Risk Factors

  • Further revenue and customer declines as the direct-selling model faces structural headwinds
  • Additional impairment charges if the Rhyz segment or goodwill continues to deteriorate
  • Inability to refinance debt or maintain liquidity if cash burn accelerates
  • Failure of Prysm iO or India launch to reverse the sales force attrition trend

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-032025
Document: ef20079831_8k.htm0001140361-26-032025
Document: 0001140361-26-032025-index-headers.html0001140361-26-032025
Document: 0001140361-26-032025-index.html0001140361-26-032025
Document: 0001140361-26-032025.txt0001140361-26-032025
8-K Data (Synthetic)0001140361-26-032025
4 reports for NUS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NUS — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
8-K
BEARISH ★ 7/10
$4.87 $4.85▲ +0.41%▼ −0.65%$4.61 (+5.34%)
Jun 12, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$5.47 $5.23▲ +4.39%▲ +6.17%$4.61 (+15.72%)
May 8, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$6.63 $5.44▼ −17.95%▼ −17.64%$4.61 (−30.47%)
Apr 3, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$7.52 $7.05▼ −6.25%▼ −15.23%$4.61 (−38.70%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (34h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access